SLAMF7 Targeted Therapies
1 drugsAbout SLAMF7
SLAMF7 (CD319 or CRACC) is a cell surface receptor in the SLAM family expressed on immune and malignant cells. It modulates immune responses and tumor cell behavior, making it a target in oncology.
Currently, there is no genetic evidence directly linking SLAMF7 to specific diseases. However, its role in modulating immune responses and tumor cell behavior supports therapeutic intervention.
SLAMF7 is targeted by one FDA-approved antibody drug, EMPLICITI (elotuzumab), developed by Bristol-Myers Squibb for oncology indications. EMPLICITI was first approved in 2015.
Top SLAMF7 Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting SLAMF7.
The market is highly concentrated, suggesting high barriers to entry or untapped potential for new players.
SLAMF7 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SLAMF7, using antibody modality.
Exploring alternative modalities like small molecules or cell therapies could provide a competitive advantage.
SLAMF7 Clinical Trials 62 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SLAMF7. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 5 | 4 | 6 | 56% |
| Phase 2 | 32 | 17 | 10 | 5 | 63% |
| Phase 3 | 15 | 5 | 3 | 7 | 63% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved SLAMF7 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SLAMF7. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
SLAMF7 Drug Approval Timeline (2015 - 2015)
The first and only drug targeting SLAMF7, EMPLICITI, was approved in 2015.
The approval timeline suggests a potentially unsaturated market with room for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 39 (12 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SLAMF7. A trial counts if an approved drug acting on SLAMF7 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.